Keyword: Japan

Seeking further returns from Taiho Ventures, Taiho Pharma just decided to multiply its investment pool sixfold to $300 million.

Japan-based Modulus Discovery raised $7.2 million in series A funds that will be used to bolster its R&D platform efforts.

HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda to work on antibody therapies.

Astellas has bought out a U.S. biotech that wants to ensure cell therapy products aren’t rejected by a patient’s immune system.

Sirt2, an enzyme long of interest to scientists studying metabolism and aging, seems to mediate the process by which the liver processes glucose.

Takeda has struck two deals this morning as it looks to make good on its ongoing R&D reorganization.

Bristol-Myers Squibb has licensed a phase 1 immuno-oncology drug from Japan’s Ono in a $40 million upfront pact.

Bayer has signed a potentially major research pact with Japan’s PeptiDream, marking the second big biobucks deal for the German pharma in the past week.

A year ago, Daiichi and partner Plexxikon suspended a trial of a rare cancer candidate on safety advice. Today they posted some very top-line results.